Pure Global
NCT01009307

Study of Blood and Cheek Cell Samples From Patients With Glioma

San Francisco Bay Area Adult Glioma Prognosis Study Protocol
University of California, San Francisco·ClinicalTrials.gov·geneticCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Brain and Central Nervous System Tumors
Drug/Device/Intervention
polymorphism analysis
Study type
Observational
Intervention type
genetic
Sponsor & location
Primary sponsor
University of California, San Francisco
Location
San Francisco, United States of America
Timeline & enrollment
Phase
N/A
Start date
Oct 01, 2001
End date
N/A
Enrollment
1709 participants
Primary outcome

Factors related to glioma survival

Summary

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory
 may help doctors learn more about changes that occur in DNA and identify biomarkers related
 to cancer. It may also help doctors predict how patients will respond to treatment.
 
 PURPOSE: This research study is looking at blood and cheek cell samples from patients with
 glioma.

ICD-10 classifications
Malignant neoplasm: Overlapping lesion of brain and other parts of central nervous systemMalignant neoplasm: Central nervous system, unspecifiedBenign neoplasm of brain and other parts of central nervous systemMalignant neoplasm of brainSecondary malignant neoplasm of other and unspecified parts of nervous system
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT01009307
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT01009307 through Pure Global AI's free database. This phase not specified trial is sponsored by University of California, San Francisco and is currently Completed. The study focuses on Brain and Central Nervous System Tumors. Target enrollment is 1709 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.